:: ym biosciences inc
October 11, 2011

Poster with broader update of trial results to be presented at ASCO - YM BioSciences Inc., today reported updated interim results for the first 60 patients with

May 1, 2012

11, 2011 /CNW/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a drug development company advancing a diverse portfolio of hematology

YM BioSciences Inc. (YMI), At 4:00PM EST: 1.63 Down 0.03 (1.81%) send us feedback. Message Boards Settings YM BioSciences Inc.

Find financial news for YM BioSciences Inc. (USA) (NYSEAMEX:YMI) using Google Finance.

YM BIOSCIENCES INC is traded at AMEX. YM BIOSCIENCES INC is a part of the Drug Manufacturers - Other industry, inside the Healthcare sector, it has NaN

September 29, 2011

Now Available: YM BioSciences Inc. (YM) - Financial and Strategic Analysis Review.

YM BioSciences Inc. Company Research (YMI) Share Prices, Charts, News, Financials, and More - Digital Look.

Correspondence: David G.P. Allan, Chairman, Chief Executive Officer, YM BioSciences Inc., 5045 Orbitor Drive, Building 11, Suite 400,. Mississauga, Ontario

4, 2011 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM BioSciences Inc. is a drug development company advancing three

October 15, 2011

Baxter International Inc. and Synovis Life Technologies, Inc. announced today a definitive agreement for YM BioSciences, Inc. (AMEX:YMI)

The Center of molecular immunology with YM Biosciences and its licensees are Other licensees for nimotuzumab include Biocon BioPharmaceuticals Ltd.

March 14th, 2011 we released our published article: "TooNiceStocks Initiates Coverage on YM Biosciences Inc. Digging Deeper into the Bullish

Shares of YM BioSciences Inc. (AMEX: YMI), a drug development company advancing a diverse portfolio of hematology and cancer-related

May 21, 2012

7, 2011 /PRNewswire/ - YM Biosciences Inc . (NYSE Amex: YMI, TSX: YM), today announced it would report updated results from its Phase I/II

About YM BioSciences Inc., YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients

Browse CNBC and partner stories, analysis, blogs and video catagorized by topic or author.

Stock quote for YM BioSciences, Inc. (YMI) - Get real-time last sale and extended hours stock prices, company news, charts, and

February 20, 2012

YM BioSciences Inc. is a cancer drug development company. It licenses research products from academic institutions and other biotechnology companies which

YM BioSciences Inc. Message board - Online Community of active, educated investors researching and discussing YM BioSciences Inc. Stocks.

Ym Biosciences Inc - 6-K - For 12/3/04 - EX-99.1 - Report of a Foreign Private Issuer - Seq. 2 - Exhibit 99.1 Ym Biosciences Adopts

YMI has a P&P score of 5/5 stars, with 29 Buy ratings to 9 Sell ratings.

August 20, 2011

Date, File Type, % Own, Filer/Issuer, Subject Company, Ticker

YM BioSciences Inc. Bldg 11, 400-5045 Orbitor Dr Mississauga, ON L4W 4Y4 Tel : (905) 629-9761. Fax: (905) 629-4959. Contact Name James Smith. Industry

Comprehensive and timely details of regulatory and non regulatory announcements from FTSE 100, 250, AIM and techMARK quoted companies.

Ym Biosciences, Inc. (YMI) rated Mkt Outperform with price target $4 by Rodman & Renshaw - GainersToday. See more Stock market

February 16, 2012

YMI - YM BioSciences Inc. (YMI) Stock Research Analysis - YM BioSciences Inc. ( YMI) Stock Research Analysis, Stock News, Stock Profile, Stock Summary,

YM BioSciences Inc. YMI (ASE). Help. Real-time prices for U.S.-listed stocks, including premarket and after hours, reflect trading through Nasdaq only.

YM BioSciences Inc., a Canadian company incorporated in 1994, principally develops cancer therapeutics. It partners with biotechnology and

424B3: YM BIOSCIENCES INC. - Find EDGAR Online-Prospectus and Proxies articles.

August 30, 2011

YMI - Short squeeze stock short interest data and short selling information for shares of Ym Biosciences Inc. Short interest stock data available

Cytopia Merger with Toronto-based YM BioSciences Inc.

Free article about 'YM BioSciences Inc and Therapure Biopharma Inc announce contract. Therapure Biopharma to perform.

CYT387: Potent Dual Inhibitor of JAK 1/2 in Phase I/II Clinical Development (YM BioSciences Inc.) ymbiosciences. Subscribe Subscribed

December 23, 2011

YM Biosciences, Inc. About Us YM BioSciences Inc., a Canadian company incorporated in 1994, principally develops cancer therapeutics. It partners with

Ibex Technologies Inc. operates in the Medicinals and botanicals sector. Therapeutics, Inc., Thallion Pharmaceuticals Incorporated and YM Biosciences Inc.

2012-01-08 YMI: Ym Biosciences Inc Institutional Investments! Ym Biosciences Inc sold some -239367 shares, change of -32.50% to total position of $879943

12, 2011 (CRWENEWSWIRE) - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), today reported updated results from the ongoing Phase I/II

October 20, 2011

Instant YM BIOSCIENCES INC (YMI) Stock Analysis. How To Buy, Sell, and Trade YMI Online. Stock Price, Quotes, and Dividends!

As at April 30, the Company had 116467644 shares outstanding. About YM BioSciences YM BioSciences Inc. is a drug development company advancing.

An opioid formulation for pulmonary administration in the treatment or management of pain, a pulmonary drug delivery device containing,

"YM BioSciences Inc.-Detailed Product Pipeline" was published on Thursday the 6th of January 2011 by Life Science Analytics. It is available

December 15, 2011

Get company or corporate stock equity shareholder selling or sales data for shares of YM Biosciences, Inc. including Fund and Institutional shareholders.

menafn: YM BioSciences Inc's net loss narrowsCAD0.9m for first quarter fiscal 2012Nov 14, 2011 (M2 EQUITYBITES via COMTEX) --Drug

YM BioSciences Inc. (AMEX:YMI) is up 27.40% in pre market trading at $1.86. YMI has YM BioSciences has a market cap of 170.40 million.

Thomas Allen, Counsel, Ym Biosciences Inc. of Ym Biosciences Inc.''s information - including email, business address, business phone, biography, title,

December 3, 2011

YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. The Company is

YM BioSciences Inc. Unauthorized recording or downloading of this event is not permitted.

YM BioSciences Inc. - Product Pipeline Review - H2 2011 YM BioSciences Inc. - Product Pipeline Review - H2 2011 Summary Global Market.

Wiki coverage on YM BIOSCIENCES INC, including quotes, charts, news, analyst research, historical returns, message boards, due diligence, fundamentals,

December 10, 2011

YM BioSciences Inc. is a life sciences product development company advancing a diverse YM BioSciences is currently advancing three late-stage products:

YM Biosciences Aktie (WKN 911799 / ISIN CA9842381050) - Aktueller Kurs, Charts Wertpapier: YM Biosciences Inc. Registered Shares o.N.

Goliath's Ym Biosciences Inc. Company Profile provides detailed company information on Ym Biosciences Inc. located in Mississauga, CANON

EV/EBITDA ratio of YM Biosciences Inc (US Listing) (CA9842381050 - YM) and its peer group for financial analysis.

April 10, 2012

YM BioSciences Inc. (AMEX: YMI) is a drug development company. It is currently advancing three clinical stage products: CYT387, a small

Stock analysis for YMI:US. Get stock price, historical stock charts & news for YM Biosciences Inc, in the Therapeutics industry.

Get the latest YMI - YM Biosciences Inc. stock rating, stock market performance data and financial news.

Ym Biosciences Inc. Stock Price (YMI) Stock Quote and real time streaming Ym Biosciences - Stock Charts, - Company Information, News, Level 2 Data,

August 26, 2011

ASX Circular. Page 1 of 2. No: 009/10. CYTOPIA LIMITED - MERGER WITH YM BIOSCIENCES. INC. BY SCHEME OF ARRANGEMENT

Preview the profile for YM BIOSCIENCES INC Agreements. Docstoc is a community for people to find and share professional documents.

YM BioSciences, Inc., an Ontario based drug development company advancing a diverse portfolio of hematology and cancer-related products,

Get the latest stock quote and more - DailyFinance is your source for YM BioSciences, Inc. (USA) stock price. Interactive Data Managed

April 25, 2012

Ym Biosciences Inc. (AMEX:YMI): On 06/30/2011, Discovery Capital Management reported holding 2327650 shares with a market value of

YM BioSciences Inc. (NYSE: YMI) is a drug development company advancing a portfolio of hematology and cancer-related products. more Post a comment

ASX Circular. Page 1 of 1. No: CYTOPIA LIMITED - MERGER WITH YM BIOSCIENCES INC. BY. SCHEME OF ARRANGEMENT. Participating

22, 2011 /CNW/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today YM BioSciences Inc. is a drug development company advancing

January 4, 2012

YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), reported preclinical results for its JAK1/JAK2 inhibitor CYT387 in multiple myeloma (MM),

Insider Overview :: YM BioSciences Inc. (T:YM), [?] Latest 10 SEDI filings (by transaction date) for YM within the last 6 months, [?] Amended

American BioSciences, Inc - Nature and Science for Better Health. American . a b "Company Profile for YM BioSciences inc (CA;YM)". Retrieved on

Ym Biosciences, Inc. (YMI) rated Buy with price target $6 by Roth Capital - GainersToday. See more Stock market recommendations, Upgrades

August 27, 2011

Results 1 - 28 The article reports on YM BioSciences Inc., a Mississauga, Ontario-based company. YM BioSciences is in a Phase 3 trial of its breast-cancer

YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a life sciences company developing a diverse portfolio of promising hematology and

YM BioSciences, Inc. (USA) (AMEX:YMI). + Watch YMI. on My Watchlist. $1.67 0.01 (+0.60%). 1/11/2012 4:00 PM

United States YM BioSciences USA Inc. P.O. Box 21747. Lehigh Valley ,

December 26, 2011

MISSISSAUGA, ON, Apr. 26, 2010 (Canada NewsWire Group) -- /CNW/ -- YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), announced today that it has filed a

YM BioSciences Inc. (Ontario, Mississauga) YM BioSciences Inc. (Ontario, Mississauga). YM BioSciences Inc. 5045 Orbitor Drive Building 11, Suite 400

YM BioSciences Inc.-Therapeutic Competitors Report YM BioSciences Inc.- Therapeutic Competitors Report Report includes a business

YM BioSciences Inc. (USA) (NYSEAMEX:YMI) witnessed volume of 3.70 million shares during last trade however it holds an average trading

November 13, 2011

View the basic YMI stock chart on Yahoo! Finance. Change the date range, chart type and compare YM BioSciences, Inc. Ordinary S against other companies.

26, 2011 /CNW/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a drug development company advancing a diverse portfolio of hematology

See how the ZeccoShare Community is trading YM Biosciences Inc (YMI)at Zecco. Get hot tips, picks, predictions and more.

Get detailed financial information on YM BioSciences USA Inc. () including real- time stock quotes, historical charts & financial news, all for free!

April 26, 2012

YMI - YM BioSciences Inc - SocialPicks. Form 6-K YM BIOSCIENCES INC For: Sep 29. Graphic_arrow1 YM BioSciences licensee Pulmokine awarded NIH

YM BioSciences Inc. (USA) (NYSEAMEX:YMI) witnessed volume of 3.62 million shares during last trade however it holds an average trading

YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse

YM BIOSCIENCES INC. Patent applications. Patent application number, Title, Published. 20100189778, OPIOID DELIVERY SYSTEM - An opioid formulation for

December 6, 2011

Latest Pulse Events on YM BioSciences Inc. by Reni Benjamin of Rodman & Renshaw, Josh Schimmer of Leerink Swann & Company, Eben Tessari of

YM BioSciences Inc (AMEX:YMI) is a Canadian company that seeks to treat cancer and cancer-related afflictions through the continued

YM BioSciences, Inc. Class Action lawsuit news, YM BioSciences, Inc. class action lawsuit information, and links to YM BioSciences, Inc. news and stock price

MISSISSAUGA, ON, March 28 /PRNewswire-FirstCall/ -- YM BioSciences Inc. , the cancer product development company, today announced

February 8, 2012

In early 2010, the Melbourne based operations of Cytopia Ltd were merged with Canadian based YM BioSciences Inc. The product portfolio of Cytopia, built

Realtimekurs YM BioSciences, Inc. in Euro. Realtime Bid: 1,27 / Ask: 1,30. Datum : 10.01.2012 19:58:16. powered by Börse Stuttgart · Realtimekurs Popup öffnen

YM BioSciences Inc. is a drug development company. It is currently advancing three clinical stage products: CYT387, a small molecule, dual

YM BioSciences Inc. (AMEX:YMI) is up 10.96% in midday trading at $1.62. YMI has traded 5.6 million shares so far today, 5 times its daily

December 11, 2011

YM BioSciences Inc. : Stock quote, stock chart, quotes, analysis, advice, financials and news for share YM BioSciences Inc. | NYSE Amex Equities: YMI | NYSE

YM BioSciences Inc. (YM.TO) principally develops cancer therapeutics. It partners with biotechnology and pharmaceutical companies as well as with drug

YM BioSciences Inc. | +1-(905)-629-9761 | E-mail/RFQ, Address, Website, Profile , Reviews, Directions & Nearby Search.

Insider trading report for Ym Biosciences, Inc YMI stock. See insider buying and selling for last 24 months.

January 4, 2012

Detailed Share Price, Charts and News for YM Biosciences Inc [TSE,YM]. Share Market Tools for Successful Investing. Global Share Market

Shared by: YM BIOSCIENCES INC Agreements. Categories Managements Discussion And Analysis - YM BIOSCIENCES INC - 9-23-2011

This one was brought to my attention by a buddy of mine. I know nothing about it other than it just got some news about approval of marketed a

Description: YM BioSciences Inc. is a drug development company advancing a diverse portfolio of promising hematology and cancer-related products.

April 16, 2012

Ms. Shulze was CEO of YM Biosciences US and President, YM Biosciences, Inc., a global biopharmaceutical organization. Prior to joining YM Biosciences in

This release is a result of our current concentration on YM BioSciences Inc. ( AMEX:YMI)(TSX:YM) and their latest corporate developments and

Results 1 - 7 of 9 About Company: YM Biosciences Inc. is developing cancer drugs based on technologies licensed primarily from international academic centers

We are reiterating our BUY rating on YM BioSciences, Inc. (NYSE AMEX: . 2 YM Biosciences Inc. press release, “YM Biosciences Announces

April 21, 2012

Mississauga, Ontario, Canada - YM BioSciences Inc. ("YM" or the "Company"), the international cancer drug development company, today announces its

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio tables (Accounting, Asset Utilization,

YM BioSciences Inc. (AMEX:YMI) announced its JAK1/JAK2 inhibitor, CYT387 has received positive opinions from the Committee for Orphan

YM BioSciences Inc. YMI (ASE). AD: Find a Broker; Help. Real-time prices for U.S.-listed stocks, including premarket and after hours, reflect trading through

November 19, 2011

FREE Canadian stocks dividend data and tools with DividendInvestors.ca. Find the most updated Ym Biosciences Inc YM Canadian stocks dividend data on the

YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM), announced that the merger of Cytopia Limited, the Australian biopharmaceutical company,

On December 17, 2010, YM BioSciences Inc. (AMEX: YMI; TSX:YM) (“YM BioSciences” or the “Company”) closed a $40 million public offering of 25000000

Ym Biosciences Inc at 5045 Orbitor Dr, Mississauga, ON L4W 4Y4.

November 15, 2011

Stock analysis for FQA:GR. Get stock price, historical stock charts & news for YM Biosciences Inc, in the Therapeutics industry.

BioWorld Online is the news service of record for the biotechnology industry and is updated every business morning. BioWorld Online will keep you up to date

About YM BioSciences. YM BioSciences Inc. is a life sciences product development company. Together with the products from YM BioSciences

YM BioSciences Inc. (NYSE: YMI) reported updated results from the ongoing Phase I/II study of its JAK1/JAK2 inhibitor, CYT387, for the

October 5, 2011

YM BioSciences Inc. is a company that identifies, develops and commercializes differentiated products principally in the area of oncology for patients worldwide.

Drug (brand / generic) Tesmilifene; Company / licensee YM BioSciences Inc; Therapy class Chemopotentiator; Product description Small molecule which boosts

YM BioSciences Inc. (AMEX: YMI) develops, markets, and commercializes hematology and cancer-related products in the drug development

Digging Deeper into the Bullish Sentiment and Upcoming Catalyst in Early June 2011 Why YM BioSciences Inc. will continue its uptrend?

November 13, 2011

YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today announced it would report updated results from its Phase I/II myelofibrosis study of CYT387,

YM BioSciences Inc., today reported preclinical results for its JAK1/JAK2 inhibitor CYT387 in multiple myeloma (MM), published in the advance

Develops cancer therapeutics, mainly through partnerships and joint ventures. Lists products and their development phases, news, corporate and financial

Many YM BioSciences Inc. products on Amazon and other vendors for best prices !

February 27, 2012

YM BioSciences' detailed financials; Comprehensive pipeline breakdown, including molecular targets & partnerships. 17 years of in-depth BioPharma industry

YM BioSciences Inc. · Mississauga, ON Canada(NYSE Amex: YMI). Buy a report on 15 executives listed for YM BioSciences Inc.'s Mississauga, ON location.

YM BioSciences Inc. - ym. YM BioSciences Inc. ym go to snapshot add to favorites. post. see all posts, Overall Quality 2+, Overall Quality 3+, Overall Quality 4+

Get detailed financial information on YM BioSciences Inc. (USA) (NYSEAMEX: YMI) including real-time stock quotes, historical charts & financial news, all for

February 16, 2012

Vien Brewster, Controller, Ym Biosciences Inc. of Ym Biosciences Inc.''s information - including email, business address, business phone, biography, title,

MISSISSAUGA, ON, June 3 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), today announced the appointment of Dr.

YM BioSciences Inc. Announces Orphan Drug Designation For JAK1/JAK2 YM BioSciences Inc. Announces Exercise Of Full Over-Allotment Option For Total

17 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that

August 6, 2011

FE Investegate announcements from YM BioSciences Inc., Research Update.

Legal Name: YM BioSciences Inc. Operating Name: YM BioSciences Inc. Mailing Address 400-5045 Orbitor Dr Bldg 11. MISSISSAUGA

Results 1 - 20 of 253 6-K, YM BIOSCIENCES INC, 11/23/11 (11/22/11). 6-K, YM BIOSCIENCES INC, 11/14/11 (09/30/11). 6-K, YM BIOSCIENCES INC, 11/14/11

Research about YM BIOSCIENCES INC., including news, information, and reports with HighBeam Business : Arrive Prepared.

February 29, 2012

Hoover's offers YM BioSciences Inc. information and related Biopharmaceuticals & Biotherapeutics facts online.

Why YM BioSciences Inc. will continue its uptrend?

Contact Information. YM BioSciences Inc. 5045 Orbitor Dr., Bldg. 11, Ste. 400. Mississauga, Ontario L4W 4Y4, Canada Tel. 905-6299761. Fax 905-6294959

MISSISSAUGA, ON, July 31 /PRNewswire-FirstCall/ - YM BioSciences Inc. , a company engaged in the acquisition, development and

September 10, 2011

Instant ALOETTE COSMETICS INC versus YM BIOSCIENCES INC Stock Quotes. Analyze ALOETTE COSMETICS INC versus YM BIOSCIENCES INC Shares.

About YM BioSciences YM BioSciences Inc. is a life sciences product development company that identifies and advances a diverse portfolio of promising

YM Biosciences Inc. stock price today: (YMI) stock quote, price history, earnings per share, technical analysis chart and breaking news.

Results 1 - 20 of 344 6-K, YM BIOSCIENCES INC, 12/12/11 (12/12/11). 6-K, YM BIOSCIENCES INC, 11/23/11 (11/22/11). 6-K, YM BIOSCIENCES INC, 11/14/11

December 12, 2011

InsideStocks is the leading provider of intraday stock and commodities realtime or delayed charts with powerful indicators and technical analysis. Search for

Company profile for YM BioSciences Inc. in Mississauga,ON. Get accurate business information including key contacts, company financials and more in the YM

YM YM BioSciences Inc. Focus Metals Inc.- Plans over the next 2-5 yrs . YM BioSciences Reports Updated Phase I/II Data for its JAK1/JAK2 Inhibitor CYT387

Seite 95 der Diskussion 'YMI in this stock? oder YM Biosciences die MISSISSAUGA, ON -- YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM),

April 9, 2012

MISSISSAUGA, Canada I December 12, 2011 I M BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today reported updated results from the

YM Biosciences Inc is a biopharmaceutical company engaged in the development of products for the treatment of cancer or cancer-related conditions.

Throughout the day, 25.37 million shares of Alcoa Inc. exchanged hands as compared to its YM BioSciences Inc. (USA) (AMEX:YMI):

YM BioSciences Inc. (AMEX: YMI) Digging Deeper into the Bullish Sentiment and TooNiceStocks research has unveiled YM Biosciences Inc. has been the

February 4, 2012

YM BioSciences, Inc. (NYSE AMEX: YMI, TSX: YM) is a life-sciences We are reiterating our BUY rating on YM BioSciences, Inc. (NYSE

Up to date analysis of YM BioSciences Inc. (YMI) and its stock by hedge fund managers and industry experts. Find out what YM BioSciences Inc. is saying about

YM Biosciences Inc is a biopharmaceutical company engaged in the development of products for the treatment of cancer or cancer-related

YM BioSciences, Inc. is a drug development company that is engaged in the Gilbert Wenzel, 54 Director, Ym Biosciences, Inc., Venus Remedies Ltd.

August 7, 2011

YM BioSciences Inc. Cancer drug Development Company, includes tesmilifene, a small molecule chemopotentiator (for taxanes and anthracyclines).

This was a T! call friday afternoon - I added. PR in the AH friday night Ym Biosciences Announces Results of Randomized Nimotuzumab Study

Hoovers company profile of YM BioSciences Inc.. Find detailed business information such as key executives, financials and other corporate data on YM

Get detailed financial information on YM BioSciences Inc. (TSE:YM) including real-time stock quotes, historical charts & financial news, all for free!

December 14, 2011

YM BIOSCIENCES INC COM NPV Toronto: YM.TO,TSE:YM technical analysis and research for investors, will it rise or fall?, come and read

YM BioSciences Reports Updated Phase I/II Data For Its JAK1/JAK2 Inhibitor CYT387 At ASH 2011 - PR Refresh Stock Quote for YM Biosciences Inc. - YMI

US:YMI - Get Stock quote detail for YM BioSciences Inc. Stock quotes include the latest US:YMI market price and fundamental investing data, price charts.

Rimon Therapeutics Ltd., Ontario. Stem Cell Therapeutics Corp., Alberta. StemPath Inc., Ontario. Variation Biotechnologies Inc., Quebec. YM BioSciences Inc.

August 7, 2011

In our complete report available for purchase the company is compared to: Ondine Biomedical Incorporated, YM Biosciences Inc and Isotechnika Pharma

Stock market news and stock research. Financial news, stock news and stock makrket update about the stocks, ETF and mutual funds listed on the NYSE, AMEX

FE Investegate announcements from YM BioSciences Inc., Directorate Change.

YM BioSciences Inc. (USA) (NYSEAMEX:YMI) is a drug development company advancing a diverse portfolio of hematology and cancer-related products.

May 16, 2012

The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2012. All rights

26, 2011 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a drug development company advancing a diverse portfolio of

Credit & Investment Research, Thomson StreetEvents: YM BioSciences Inc. Conference Call & Analyst Meeting to discuss the interim results

YM BIOSCIENCES INC (FQA:GR) stock price & investing information. Find YM BIOSCIENCES INC historical stock quotes, key competitors, stock data,

April 28, 2012

S, 2008-02-14 09:49:12, YM BIOSCIENCES INC · n/a · Xmark Opportunity Partners, 1.7%, view. B, 2007-12-20 16:21:25, YM BIOSCIENCES INC · n/a

YM BioSciences Inc. is a drug development company advancing three clinical- stage products: CYT387, a small molecule, dual inhibitor of

Get YM BioSciences Inc. business contacts for Healthcare,

YM BioSciences Inc.-Detailed Product Pipeline, published March 2011, pages 174, YM BioSciences Inc.-Detailed Product Pipeline provides up to date insight

March 24, 2012

YM BioSciences Inc. (USA) (NYSEAMEX:YMI) is a drug development company advancing a diverse portfolio of hematology and cancer-related

"YM BioSciences Inc.-Therapeutic Competitors Report" was published on Thursday the 6th of January 2011 by Life Science Analytics.

View iStockAnalyst's scorecard for YM BioSciences, Inc.(YMI). Learn more about investing into YMI from the industry experts. Track YMI sentiment survey and

Therapure Biopharma to perform fill/finish of nimotuzumab - MISSISSAUGA ON Dec. 17 / David Allan ChairmaNimotuzumab is a humanized

February 28, 2012

YM BioSciences Inc. (USA) NYSEAMEX:YMI recently reported operational and financial results for its first quarter of fiscal 2012, ended

20 PRNewswire - YM BioSciences Inc. (NYSE Amex YMI, TSX YM), a life sciences product development company advancing a diverse portfolio

Register now for FREE live YM BioSciences Inc share prices, YM BioSciences Inc stock quotes, charts, trades and FREE YM BioSciences Inc company

Equities research analysts at Collins Stewart initiated coverage on shares of YM BioSciences Inc. (NYSE: YMI) in a research note to investors

November 14, 2011

Do not invest in Ym Biosciences, Inc (YMI) stock before you read this free research report on the company.

EV / Revenue Use Average, YM YM BioSciences Inc. DNA Genentech, Inc. Change, AMGN Amgen, Inc. Change, GILD Gilead Sciences, Inc. Change, CELG

YM BioSciences Inc. (NYSE:YMI) is a drug development company advancing a portfolio of hematology and cancer-related products.

Breaking news, pictures, videos and more from around world the about YM BioSciences, Inc..

August 23, 2011

We are reiterating our BUY rating on YM BioSciences, Inc. (NYSE April 21, 2010, YM BioSciences, Inc. announced data for CYT387 in the

YM BioSciences Inc: The first stock on the list is biopharmaceutical company YM BioSciences Inc. (AMEX: YMI), which develops products for

YM BioSciences Inc. (USA) (NYSEAMEX:YMI) witnessed volume of 7.57 million shares during last trade however it holds an average trading

YM BioSciences Inc.-Therapeutic Competitors Report Report includes a business summary, tabular representation of the number and percentage of products in

November 2, 2011

22, 2011 /CNW/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today reported that, in view of the unusual market activity in the common

YM BioSciences Inc. - Product Pipeline Review - H2 2011 - new company profile.

YM BioSciences Inc. (YM BioSciences) is a publicly held Canada-based company. The company is principally engaged in the development of products for the

T.YM YM BioSciences Inc. Inter-Citic Minerals Inc. | T.ICI. 10/1/2010. Focus Metals Inc.- Plans over the next 2-5 yrs. Focus Metals Inc. | V.FMS. 11/25/2010

October 19, 2011

17 /PRNewswire-FirstCall/ - David Allan , Chairman and CEO of YM BioSciences Inc. and Thomas Wellner , President and CEO of Therapure Biopharma Inc.

YM BioSciences Inc. Stock Message Board, YMI Stock Quote, YMI Stock Chart, YMI Stock News.

4, 2011 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today reported preclinical results for its JAK1/JAK2 inhibitor CYT387

YMI - YM BioSciences Inc - SocialPicks. Form 6-K YM BIOSCIENCES INC For: Sep 29. Graphic_arrow1 YM BioSciences licensee Pulmokine

January 15, 2012

YMI Stock HQ. In-depth research & opinions on YM BioSciences Inc. (YMI) from expert traders and investors who follow YMI closely.

YM BioSciences Inc. (YMI) announced on Monday that preliminary results of a Phase II study evaluating the safety and efficacy of nimotuzumab

Press Release Source: YM BioSciences Inc. On Tuesday March 30, 2010, 7:30 am EDT MISSISSAUGA, ON, March 30 /PRNewswire-FirstCall/

FE Investegate announcements from YM BioSciences Inc., Regulatory Approval.

September 24, 2011

YM BioSciences Inc., a drug development company advancing a diverse portfolio of hematology and cancer-related products, today reported

YM BioSciences Inc. Mergers and Acquisitions Snapshot, M&A Deals Timeline, Stakes, Divestitures.

Stock analysis for YM:CN. Get stock price, historical stock charts & news for YM Biosciences Inc, in the Therapeutics industry.

YM BioSciences Inc. announces it has closed its previously announced “ registered YM BioSciences Inc. and Therapure Biopharma Inc. announce contract

April 1, 2012

Dr. Nick Glover, Ph.D., is the President, Chief Executive Officer, Director of YM BioSciences Inc. Dr. Glover is the President and Chief Executive Officer of the

YM BIOSCIENCES INC (YM:CN) stock price & investing information. Find YM BIOSCIENCES INC historical stock quotes, key competitors, stock data, executives

YM BioSciences Inc. completes recruitment for tesmilifene pilot Phase II trial in prostate cancer; 70% response rate reported. Posted September

YM BioSciences Inc. Therapeutic Competitor Report contains detailed information on pipelines by phase and therapeutic indication as well as management

November 26, 2011

View the basic YM.TO stock chart on Yahoo! Finance. Change the date range, chart type and compare YM BIOSCIENCES INC against other companies.

Gary Floyd, YM BioSciences Inc., Berwyn, PA - Business Contact Information in Jigsaw's business directory. Jigsaw's business directory provides complete

YM Biosciences Inc. microsite contains Pharmaceuticals BioPharma information on product specifications, white papers, and company information. Compare YM

YM BioSciences is a bio-pharmaceutical company which is evaluating lead compound nimotuzumab (nimo) (an IgG1, humanized epidermal

October 21, 2011

Get YMI stock quote information for YM Biosciences Inc, including a stock overview, one-click scorecard, industry position, and the latest headlines.

YM BioSciences Inc.-Therapeutic Competitors Report, published March 2011, pages 198, YM BioSciences Inc.-Therapeutic Competitors Report Report includes

YM BioSciences Inc. (YM) is a drug development company advancing a diverse portfolio of hematology and cancer-related products.

Health care industry insiders provide analysis & data on pharma biotech device & diagnostic company strategy & trends. Deals & technology

October 7, 2011

YM BioSciences Inc. (NYSE:YMI), reported updated results from the ongoing Phase I/II study of its JAK1/JAK2 inhibitor, CYT387, for the

The YM BioSciences Inc. (USA) (YMI) Competitors by Product report shows YM The report then maps YM BioSciences Inc. (USA) competing products to the

JAK1/2 inhibitor currently in Phase II clinical study in myelofibrosis- MISSISSAUGA, ON, Aug. 10 /CNW/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX :YM),

Analysis of YMI, YM BIOSCIENCES INC in American and Canadian Stock Markets NYSE, NASDAQ, AMEX, OTC, TSX,and CDNX, End-of-Day Stock Data, Alert

October 23, 2011

YM BioSciences Provides Update on the Development Program for Nimotuzumab- Eleven abstracts on nimotuzumab to be presented at ASCO

Ym Biosciences USA Inc company profile in Chesterbrook, PA. Our free company profile report for Ym Biosciences USA Inc includes business information such

10 /CNW/ - YM BioSciences Inc. (AMEX: AIM:YMBA), the cancer product development company, announced to entered into an exclusive worldwide license

12, 2011 /PRNewswire/ - YM BioSciences Inc. (YMI), today reported updated results from the ongoing Phase I/II study of its JAK1/JAK2 inhibitor, CYT387.

February 3, 2012

Ym Biosciences Inc is a Canada company in 5045 Orbitor Dr, Mississauga, ON L4W, Canada, belongs to PHARMACEUTICAL PRODUCTS WHOLESALE

Market valuation multiples for YM Biosciences Inc (US Listing) (CA9842381050 - YM) compared to its main competitors.

Find out the latest news headlines for YM BioSciences, Inc. Ordinary S (YMI).

YM BioSciences Inc. is advancing two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor

December 16, 2011

Share price chart for YM Biosciences, Inc.-YMI from Morningstar. Chart with index and company comparisons for YM Biosciences, Inc.-YMI.

YM BioSciences Inc. (AMEX:YMI), announced preclinical results for JAK1/JAK2 inhibitor CYT387 in multiple myeloma (MM), published in the

Get SEC filings for YM Biosciences, Inc. (YMI), including Annual Report (10k) and Quarterly Report (10Q).

YM BioSciences, Inc.Get latest news on YM BioSciences, Inc., from firstpost and other sources worldwide. Photos, Articles, Stories, Quotes, Images and more on

April 3, 2012

YM BioSciences Inc. (AMEX:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients

YM Biosciences Inc. | 905-629-9761 | 905-629-4959 | 5045 Orbitor Dr, Suite 400, Mississauga, ON.

Ym Biosciences Inc in Mississauga with phone number, address, and interactive map. Call Ym Biosciences Inc now free of charge or write a review.

YM Biosciences, Inc. (YMI) Stock picks and trading strategies.

May 7, 2012

'ym biosciences inc' related content. Editorial content matching 'ym biosciences inc'. Content with tags matching 'ym biosciences inc':

YM BioSciences Inc. (YM) is a drug development company advancing a diverse portfolio of hematology and cancer-related products. The Company is advancing

MISSISAUGA, ON, Oct. 31, 2011 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM) today announced that preliminary results of a Phase II study

YM BioSciences Inc.(AMEX:YMI, TSX:YM, AIM:YMBA), a company engaged in the acquisition,development and commercialization of oncology

April 13, 2012

This page contains information about YM BioSciences Inc.(YM)

12, 2011 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today reported updated results from the ongoing Phase I/II study of

YM BioSciences Inc. - Product Pipeline Review - H2 2011 Summary Global Market Direct's pharmaceuticals report,

Delex Therapeutics, Inc. (Acquired by YM BioSciences, Inc.) About Us YM BioSciences is a life sciences product development company that identifies and

January 21, 2012

MISSISSAUGA, Ont. - YM BioSciences Inc. (TSX:YM) posted a $31.2-million annual loss for fiscal 2011 as the drug development company's

YM BIOSCIENCES INCSEC FILINGS. View all filings and insider trading for YM BIOSCIENCES INC.

YM BioSciences Inc.-Deals & Alliances Report, YM BioSciences Inc.-Deals & Alliances ReportReport contains the company's contact information, business

YM BioSciences Inc. Global Public & Private Company Pipeline Report contains detailed information on pipelines by phase and therapeutic indication as well as

January 29, 2012

YM Biosciences Inc share price (). View the share price, trading information for YM Biosciences Inc and other shares. Hargreaves Lansdown gives you free

YM BioSciences Inc. financial and business news, updates, and information from The New York Times and other leading providers.

Insider Trading. News. Log In; Sign Up. Main · Insider Purchases · Insider Sales · Browse Companies · Home > Insider Trading > Y M Biosciences Inc > Profile

YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM) today announced results of a collaboration with researchers at the University of Toronto for the

November 7, 2011

YM BioSciences Inc. is a drug development company advancing three products: CYT387, a small molecule, dual inhibitor of the JAK1/JAK2

What stock price is YMI? Get the latest news and information about YM BioSciences Inc. in real-time. Find out what professional investors, analysts, and hedge

YM Biosciences Shareholder Update. 23 March 2011. This is an occasional update of some of the important news about YM BioSciences Inc. As you are aware,

Home › YM Biosciences Inc Kontanten AB · Bessemer Venture Partners investment in Cerulean Pharma Inc (103917) · Craig Heim employment at Wisconsin


Name:

Email:

Phone:

Info:

Copyright © 2010-2012 onlinedrugsprice.com